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LETTERS
Risk of Coronary Heart Disease and Mortality
for Adults With Subclinical Hypothyroidism
To the Editor: In their study, Dr Rodondi and colleagues1
addressed the issue of the relationship between subclinical
hypothyroidism and coronary heart disease (CHD) or
mortality. Previous large prospective cohort studies have
provided conflicting results about this extensively studied
association. In the study by Rodondi et al, an attempt to
reduce the effects of several confounders (including age,
sex, degree of thyroid stimulating hormone [TSH] eleva-
tion, and pre-existing cardiovascular disease) was per-
formed.1 However, the finding of no association of risk
with subclinical hypothyroidism for TSH concentration up
to 10.0 mIU/L may be flawed because it did not provide
information about the body mass index (BMI) of the
patients diagnosed with subclinical hypothyroidism.
This might be a problem because subclinical hypothy-
roidism, especially when characterized by minor increases
in serum TSH levels, is frequently observed among obese
patients.2-4 The elevated serum TSH found in obese (and par-
ticularly in morbidly obese) patients may be a mere conse-
quence of the excess body weight rather than a condition
of primary thyroid failure.2-4 This concept would imply that
obese patients with a moderate elevation in serum TSH would
not experience increased systemic vascular resistance, al-
tered endothelial function, increased atherosclerosis, al-
tered coagulability, and lipid abnormalities, which ac-
count for the increased risk of CHD associated with
subclinical hypothyroidism.5
Positive tests for thyroid autoantibodies are the only
parameters able to discriminate between true subclinical
hypothyroidism and obesity-induced hyperthyrotro-
pinemia.3 Because thyroid antibodies were not taken into
account in diagnosing subclinical hypothyroidism in the
study by Rodondi et al, the conclusions may have been
biased. Indeed, obese patients with a moderately
increased TSH (up to 10 mIU/L) may include a subgroup
of patients who are not truly hypothyroid, thus underes-
timating the real CHD risk associations of subclinical
hypothyroidism (defined as high serum level of TSH with
normal free thyroxine levels and positive test results for
thyroid antibodies).
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To the Editor: Dr Rodondi and colleagues1 assessed the
risk of CHD and total mortality for adults with subclini-
cal hypothyroidism. In this study, the hazard ratio (HR)
for CHD events was 1.00 (95% confidence interval [CI],
0.86-1.18) for a TSH level of 4.5 to 6.9 mIU/L, 1.17 (95%
CI, 0.96-1.43) for a TSH level of 7.0 to 9.9 mIU/L, and
1.89 (95% CI, 1.28-2.80) for a TSH level of 10.0 to 19.9
mIU/L. They concluded that subclinical hypothyroidism
was associated with an increased risk of CHD events and
CHD mortality in persons with higher TSH levels, par-
ticularly in those with a TSH concentration of 10 mIU/L
or greater, and that minimal TSH elevations were not
associated with an increased risk of CHD events and
CHD mortality. However, they did not verify the CHD
events and CHD mortality among those within the refer-
ence range of TSH levels.
TSH levels within the reference range may be positively
associated with BMI2 and inversely associated with insulin
sensitivity.3 We investigated the relationship between thy-
roid function and carotid intima-media thickness (CIMT)
in 643 participants with euthyroid status and demon-
strated that CIMT was independently associated with thy-
roid function within the normal reference range, which
suggests increased cardiovascular risk in persons with low-
normal thyroid function.4 Furthermore, in a population-
based prospective cohort study, TSH levels even within the
reference range were positively and linearly associated
with CHD mortality in women.5
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One possible explanation for the difference in findings
is the effect of confounding factors. In the study by Åsvold
et al,5 a modest attenuation of the association of TSH level
with CHD mortality was observed after adjustment for blood
pressure and serum lipids, suggesting that the effect of TSH
may be at least partially mediated by these factors. Further
analysis should be conducted with a similar strategy in the
study by Rodondi et al, aimed at those within the reference
range of TSH.
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In Reply: We agree with Dr Rotondi and colleagues and
Dr Takamura and colleagues that the mediating factors
between subclinical hypothyroidism and CHD remain to
be determined, since in our study the associations
between subclinical hypothyroidism and CHD remained
of similar magnitude after adjustment for traditional car-
diovascular risk factors. Rotondi et al hypothesized that
inclusion of obese individuals might explain the lack of
the significant association with CHD among adults with
minimal TSH elevations. We disagree with this hypoth-
esis for several reasons.
First, TSH level in most obese individuals is usually in
the normal or upper normal range (2.5-4.5 mIU/L),1 even
in severe obesity,2 so misclassification should be uncom-
mon. Second, further adjustment for BMI (available in 10
of the 11 cohort studies) yielded similar risk estimates, as
shown in Table 3 of our article. Third, we have performed
a further sensitivity analysis excluding obese participants
with a BMI of 30 or more (calculated as weight in kilo-
grams divided by height in meters squared) and found simi-
lar results: the age and sex-adjusted HR for CHD events was
1.04 for a TSH level of 4.5 to 6.9 mIU/L (95% CI, 0.91-
1.20), 1.18 for a TSH level of 7.0 to 9.9 mIU/L (95% CI, 0.93-
1.49), and 1.95 for a TSH level of 10 mIU/L or more (95%
CI, 1.27-2.99; P=.002 for trend), with corresponding HRs
for CHD mortality of 1.07 (95% CI, 0.87-1.32), 1.45 (95%
CI, 1.04-2.03), and 1.78 (95% CI, 1.21-2.62; P=.001 for
trend), respectively. However, as mentioned in our limita-
tions, some participants might have had spontaneous reso-
lution of subclinical hypothyroidism (normalization of TSH
without treatment), which might be particularly common
in participants with TSH levels of 4.5 to 6.9 mIU/L. Fur-
ther studies among adults with persistent subclinical hy-
pothyroidism are needed.
Regarding the lack of data on thyroid autoantibodies, the
commonly accepted definition of subclinical hypothyroid-
ism3,4 is a serum TSH concentration above the statistically
defined upper limit of the reference range with normal serum
free T4 concentration and does not include thyroid
autoantibodies. Differences in risks of subclinical hypothy-
roidism with and without thyroid autoantibodies should be
examined in future studies.
We agree with Takamura et al that the issue of CHD risks
related to TSH within the euthyroid range is very interest-
ing, but this question was outside the scope of this specific
study.
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Well-being of Patients With Dementia
and Their Caregivers After a Biobehavioral
Home-Based Intervention
To the Editor: Dr Gitlin and colleagues1 reported the
results of the Care of Persons with Dementia in their Envi-
ronments (COPE) randomized controlled trial, assessing a
biobehavioral home-based intervention to support physical
function and quality of life for patients with dementia
and the well-being of their caregivers. The authors
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